Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma

被引：0
|
作者：
Wen, P. Y. [1 ]
Shih, K. [2 ]
Schiff, D. [3 ]
Brachmann, R. [4 ]
Weitzman, R. [4 ]
Cloughesy, T. [5 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Sarah Cannon Res Insititute, Neurooncol, Nashville, TN USA
[3] Univ Virginia Hlth Syst, Neurol, Charlottesville, VA USA
[4] BeiGene USA Inc, Clin Dev, Emeryville, CA USA
[5] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)
    Shih, Kent
    Schiff, David
    Kim, Lyndon
    Battiste, James
    Campian, Jian
    Puduvalli, Vinay
    Wen, Patrick
    Cloughesy, Timothy
    van den Bent, Martin
    Pirzkall, Andrea
    Wood, Katie
    Wei, Rachel
    Du, Bing
    Mu, Song
    Ramakrishnan, Vanitha
    Walbert, Tobias
    NEURO-ONCOLOGY, 2018, 20 : 17 - 18
  • [2] PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE
    Piotrowski, Anna
    Puduvalli, Vinay
    Wen, Patrick
    Campian, Jian
    Colman, Howard
    Pearlman, Michael
    Butowski, Nicholas
    Battiste, James
    Glass, Jon
    Cloughesy, Timothy
    Schiff, David
    van den Bent, Martin
    Walbert, Tobias
    Ahluwalia, Manmeet
    Badruddoja, Michael
    Kalra, Amandeep
    Aregawi, Dawit
    Weller, Michael
    Ramakrishnan, Vanitha
    Zhang, Kathy
    Wood, Katie
    Mellinghoff, Ingo
    Shih, Kent
    NEURO-ONCOLOGY, 2019, 21 : 21 - 22
  • [3] Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors
    Johnson, M.
    Benson, B.
    Wei, R.
    Brachmann, R.
    Galsky, M. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE
    Piotrowski, Anna
    Puduvalli, Vinay
    Wen, Patrick
    Colman, Howard
    Campian, Jian
    Pearlman, Michael
    Butowski, Nicholas
    Cloughesy, Timothy
    Battiste, James
    Glass, Jon
    Schiff, David
    van den Bent, Martin
    Walbert, Tobias
    Ahluwalia, Manmeet
    Badruddoja, Michael
    Kalra, Amandeep
    Pelham, Robert
    Zhang, Kathy
    Wood, Katie
    Weller, Michael
    Shih, Kent
    NEURO-ONCOLOGY, 2020, 22 : 51 - 51
  • [5] Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma
    Yust-Katz, Shlomit
    Liu, Diane
    Yuan, Ying
    Liu, Vivien
    Kang, Sanghee
    Groves, Morris
    Puduvalli, Vinay
    Levin, Victor
    Conrad, Charles
    Colman, Howard
    Hsu, Sigmonid
    Yung, W. K. Alfred
    Gilbert, Mark R.
    CANCER, 2013, 119 (15) : 2747 - 2753
  • [6] Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
    Colman, Howard
    Raizer, Jeffrey J.
    Walbert, Tobias
    Plotkin, Scott Randall
    Chamberlain, Marc C.
    Wong, Eric T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] A PHASE 1B/2 CLINICAL STUDY OF NAPABUCASIN IN COMBINATION WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH RECURRENT OR PROGRESSED GLIOBLASTOMA MULTIFORME (GBM)
    Chi, Andrew
    DeRobles, Paula
    Foos, Emma
    Hitron, Matthew
    Mason, Warren
    NEURO-ONCOLOGY, 2020, 22 : 52 - 52
  • [8] Phase I study of sorafenib in combination with radiation therapy and temozolomide for the first-line treatment of patients with high grade glioma.
    Hottinger, A. F.
    Ben Aissa, A.
    Bodmer, A.
    Squiban, D.
    Dunkel, N.
    Maradan, N.
    Vargas, M. I.
    Weber, D. C.
    Brendel, E.
    Dietrich, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [10] Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
    Youssef, Gilbert
    Lathia, Justin
    Lee, Eudocia Quant
    Chukwueke, Ugonma Nnenna
    Lauko, Adam
    Batchelor, Tracy
    Aquilanti, Elisa
    Nayak, Lakshmi
    Myers, Alexa
    Russ, Alyssa
    Westergaard, Catharina C.
    Alban, Tyler
    Jarmula, Jakub
    Lee, Juyeun
    Vogelbaum, Michael A.
    Matsuda, Kazuko
    Reardon, David A.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345